Suchbegriffe: IBANDRONATE, . Treffer: 5
Muschitz, C; Kocijan, R; Pahr, D; Patsch, JM; Amrein, K; Misof, BM; Kaider, A; Resch, H; Pietschmann, P
Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis.
Calcif Tissue Int. 2015; 96(6): 477-489.
Doi: 10.1007/s00223-015-0003-8
Web of Science
PubMed
FullText
FullText_MUG
Wagner, D; Amrein, K; Dimai, HP; Kniepeiss, D; Tscheliessnigg, KH; Kornprat, P; Dobnig, H; Pieber, T; Fahrleitner-Pammer, A
Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX.
Transplantation. 2012; 93(3):331-336
Doi: 10.1097/TP.0b013e31823f7f68
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Dimai, HP; Pietschmann, P; Resch, H; Preisinger, E; Fahrleitner-Pammer, A; Dobnig, H; Klaushofer, K; Austrian Society for Bone and Mineral Research (AuSBMR)
Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
Wien Med Wochenschr. 2010; 160(21-22):586-589
Doi: 10.1007/s10354-010-0840-z
PubMed
FullText
FullText_MUG
Dimai, HP; Pietschmann, P; Resch, H; Preisinger, E; Fahrleitner-Pammer, A; Dobnig, H; Klaushofer, K; Austrian Society for Bone and Mineral Research (AuSBMR)
Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009
Wien Med Wochenschr Suppl. 2009; (122): 1-34.
Doi: 10.1007/s10354-009-0656-x
PubMed
FullText
FullText_MUG
Google Scholar
Fahrleitner-Pammer, A; Piswanger-Soelkner, JC; Pieber, TR; Obermayer-Pietsch, BM; Pilz, S; Dimai, HP; Prenner, G; Tscheliessnigg, KH; Hauge, E; Portugaller, RH; Dobnig, H
Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
J Bone Miner Res. 2009; 24(7): 1335-1344.
Doi: 10.1359/jbmr.090216
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar